| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.35 | 0.02 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |